Design Therapeutics 10-Q: Q3 Loss $20.3M, $208.6M Cash, ATM Upsized to $200M
DSGN sits 73% above its 52-week low of $6.16.
Summary
Design Therapeutics' Q3 10-Q confirms the $20.3 million quarterly loss and $208.6 million cash position, and discloses it sold 3.1 million ATM shares for $37.1 million net while moving to raise the ATM ceiling to $200 million.
Key Events · Earnings and Guidance · DSGN
-
Q3 Loss Widens to $20.3M
Net loss was $20.3 million, or $0.32 per share, versus $17.0 million ($0.30) a year earlier; R&D rose to $16.9 million from $14.6 million.
-
ATM Upsized to $200M
Design will file a prospectus supplement to raise the ATM Program ceiling from $100.0 million to $200.0 million, expanding the dilution overhang.
-
3.1M ATM Shares Already Sold
3,140,522 shares were sold under the ATM in the nine months to September 30, 2026 for about $37.1 million net; $36.4 million remained available before the increase.
-
Cash Covers More Than 12 Months
Cash, equivalents and investments totaled $208.6 million at September 30, 2026, down $11.2 million from $219.8 million at December 31, 2025.
Analysis · DSGN · Life Sciences
The quarterly numbers match this morning's 8-K, but the 10-Q carries financing detail the 8-K did not. Design has already sold 3,140,522 shares under its ATM in 2026 for roughly $37.1 million net, and it will file a prospectus supplement to raise the ATM ceiling from $100 million to $200 million. With $208.6 million of cash and investments and a $58.1 million nine-month operating loss, the balance sheet funds operations for more than 12 months, but the enlarged ATM is a standing dilution overhang on top of 17.8 million options already outstanding. The clinical timeline is the swing factor: 12-week RESTORE-FA data for DT-216P2 has slipped to Q1 2027, with registrational plans due in Q4 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DSGN was trading at $10.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $665.2M. The 52-week trading range was $6.16 to $17.25. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.